Abstract
Objective
To examine the relationship of baseline levels of serum TGF-β1 to the subsequent risk of death from pancreatic cancer in a nested case–control study.
Methods
The cases were 85 persons who had provided a blood sample at baseline and subsequently died of pancreatic cancer during the study period. For each case, three controls were randomly selected from among the cohort participants, and were matched for each case by sex, age (±1 year), and study area. Serum TGF-β1 levels were measured with enzyme-linked immunosorbent assay (ELISA). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from conditional logistic models.
Results
The mean of serum TGF-β1 levels was significantly higher among cases than among controls (p = 0.01). Individuals with serum TGF-β1 levels in the highest quartile had a 2.5-fold increase in risk as compared with those in the lowest quartile (OR, 2.5; 95% CI, 0.9–6.9), after adjustment for month of blood draw, cigarette smoking, body mass index and history of diabetes. Excluding 12 pancreatic cancer deaths that occurred within three years of follow-up did not alter the positive association.
Conclusion
Our prospective data indicate that high serum TGF-β1 levels may be associated with an increased risk of death from pancreatic cancer.
Similar content being viewed by others
References
Statistics and Information Department, Minister’s Secretariat. Vital Statistics of Japan (2003) Ministry of Health and Welfare, Tokyo
Lin Y, Tamakoshi A, Wakai K, et al (1998) Descriptive epidemiology of pancreatic cancer in Japan. J Epidemiol 8:52–59
Lin Y, Tamakoshi A, Kawamura T, et al (2001) An epidemiological overview of environmental and genetic risk factors of pancreatic cancer. Asian Pac J Cancer Prev 2:271–280
Koopmann J, Buckhaults P, Brown DA, et al (2004) Serum macrophage inhibitor cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10:2386–2392
Koopmann J, Zhang Z, White N, et al (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860–868
Korc M (1998) Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 7:25–41
Ivanovic V, Melman A, Davis-Joseph B, Valcic M, Geliebter J (1995) Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1:282–284
Shim KS, Kim KH, Han WS, Park EB (1999) Elevated serum levels of transforming growth factor-β1 in patients with colorectal carcinoma. Cancer 85:554–561
Sheen-Chen SM, Chen HS, Sheen CW, Eng HL, Chen WJ (2001) Serum levels of transforming growth factor β1 in patients with breast cancer. Arch Surg 136:937–940
Kleeff J, Friess H, Simon P, et al (1999) Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Dig Dis Sci 44:1793–1802
Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor β in human disease. New Engl J Med 342:1350–1358
Derynck R, Akhurst RJ, Balmain A (2001) TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29:117–129
Massague J, Blain SW, Lo RS (2000) TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103:295–309
Heldin CH, Miyazono K, tenDijke P (1997) TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390:465–471
Ohno Y, Tamakoshi A, and the JACC Study Group (2001) Japan Collaborative Study for Evaluation of Cancer Risk (JACC Study). J Epidemiol 11:144–150
Mantel N (1963) Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 58:690–700
Piek E, Roberts AB (2001) Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 83:1–54
Hahn SA, Schutte M, Hoque AT, et al (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353
Esmatjes E, Flores L, Lario S, et al (1999) Smoking increases serum levels of transforming growth factor-β in diabetic patients. Diabetes Care 22:1915–1916
Flores L, Vidal M, Abian J, et al (2004) The effects of smoking and its cessation on 8-epi-PGF2alpha and transforming growth factor-beta 1 in Type 1 diabetes mellitus. Diabet Med 21:285–289
Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A (2002) Effects of tobacco smoke on the secretion of interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta from peripheral blood mononuclear cells. Oral Microbiol Immunol 17:331–336
Cucina A, Corvino V, Sapienza P, et al (1999) Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells. Biochem Biophys Res Commun 13:306–312
Acknowledgments
The authors thank Dr. Kunio Aoki, Professor Emeritus, Nagoya University School of Medicine and the former chairman of the JACC Study Group, and Dr. Haruo Sugano, the former Director of the Cancer Institute of the Japanese Foundation for Cancer Research, for their great contribution to the initiation of the JACC study.
The present investigators involved in the JACC Study and their affiliations are as follows: Akiko Tamakoshi (chairman of the study group), Nagoya University Graduate School of Medicine; Dr. M. Mori, Sapporo Medical University School of Medicine; Dr. Y. Motohashi, Akita University School of Medicine; Dr. I. Tsuji, Tohoku University Graduate School of Medicine; Dr. Y. Nakamura, Jichi Medical School; Dr. H. Iso, Institute of Community Medicine, University of Tsukuba; Dr. H. Mikami, Chiba Cancer Center; Dr. S. Hashimoto, Fujita Health University School of Medicine; Dr. Y. Inaba, Juntendo University School of Medicine; Dr. Y. Hoshiyama, Showa University School of Medicine; Dr. H. Suzuki, Niigata University Graduated School of Medicine and Dental Science; Dr. H. Shimizu, Gifu University School of Medicine; Dr. H. Toyoshima, Nagoya University Graduated School of Medicine; Dr. S. Tokudome, Nagoya City University Graduated School of Medicine; Dr. Y. Ito, Fujita Health University School of Health Sciences; Dr. S. Kikuchi, Aichi Medical University School of Medicine; Dr. A. Koizumi, Graduate School of Medicine and Faculty of Medicine, Kyoto University; Dr. T. Kawamura, Kyoto University Center for Student Health; Dr. Y. Watanabe, Kyoto Prefectural University of Medicine, Research Institute for Neurological Diseases and Geriatrics; Dr. T. Miki, Kyoto Prefectural University of Medicine; Dr. C. Date, Faculty of Human Environmental Sciences, Mukogawa Women’s University; Dr. K. Sakata, Wakayama Medical University; Dr. T. Nose, Tottori University Faculty of Medicine; Dr. N. Hayakawa, Research Institute for Radiation Biology and Medicine, Hiroshima University; Dr. T. Yoshimura, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Japan; Dr. K. Fukuda, Kurume University School of Medicine; Dr. N. Okamoto, Kanagawa Cancer Center; Dr. T. Ishibashi, Asama General Hospital; Dr. H. Shio, Shiga Medical Center, Dr. Y. Ohno, Asahi Rosai Hosipital and Dr. K. Tajima, Aichi Cancer Center Research Institute. The former investigators involved in the JACC study and their affiliations are as follows: Dr. K. Aoki, Aichi Cancer Center; Dr. S. Tominaga, Aichi Cancer Center Research Institute; Dr. S. Anzai, Dr. T. Kawaguchi, Dr. K. Nakamura, Dr. M. Masaki, Showa University School of Medicine; Dr. S. Kanamori, Dr. M. Morimoto, Dr. S. Yoshimura, Shiga Medical Center for Adults; Dr. S. Kamiyama, Dr. Y. Takizawa, Dr. N. Hachiya, Akita University School of Medicine; Dr. K. Kawai, Dr. S. Nakagawa, Dr. H. Watanabe, Kyoto Prefectural University of Medicine; Dr. M. Kurihara, Research Institute for Radiation Biology and Medicine, Hiroshima University; Dr. Y. Komachi, Institute of Community Medicine, University of Tsukuba; Dr. R. Sasaki, Aichi Medical University; Dr. M. Sugita, Toho University School of Medicine; Dr. I. Sugimura, Asahikawa Kosei Hospital; Dr. T. Tanaka, Chigasaki Public Health Center; Dr. T. Hirohata, Kyushu University School of Medicine; Dr. I. Fujimoto, Center for Adult Diseases, Osaka; Dr. M. Matsuzaki, Chigasaki Public Health and Welfare Center; Dr. H. Miyake, Sapporo Medical University School of Medicine; Dr. M. Murata, Chiba Cancer Center; Dr. S. Morio, Kanagawa Cancer Center; Dr. H. Yanagawa, Jichi Medical School and Dr. S. Watanabe, Tokyo University of Agriculture.
This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas (C) (2) (No.13220019) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The JACC Study has also been supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Nos. 61010076, 62010074, 63010074, 1010068, 2151065, 3151064, 4151063, 5151069, 6279102 and 11181101).
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, Y., Kikuchi, S., Tamakoshi, A. et al. Serum transforming growth factor-β1 levels and pancreatic cancer risk: a nested case–control study (Japan). Cancer Causes Control 17, 1077–1082 (2006). https://doi.org/10.1007/s10552-006-0048-0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10552-006-0048-0